BR112015018317A8 - Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica - Google Patents

Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica

Info

Publication number
BR112015018317A8
BR112015018317A8 BR112015018317A BR112015018317A BR112015018317A8 BR 112015018317 A8 BR112015018317 A8 BR 112015018317A8 BR 112015018317 A BR112015018317 A BR 112015018317A BR 112015018317 A BR112015018317 A BR 112015018317A BR 112015018317 A8 BR112015018317 A8 BR 112015018317A8
Authority
BR
Brazil
Prior art keywords
compound
salt
formula
pharmaceutical composition
processes
Prior art date
Application number
BR112015018317A
Other languages
English (en)
Other versions
BR112015018317B1 (pt
BR112015018317A2 (pt
Inventor
Buon Christophe
Cantin Louis-David
Hu Yun-Jin
Luo Xuehong
Jerzy Tomaszewski Miroslaw
Original Assignee
Neomed Inst
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomed Inst, Bellus Health Cough Inc filed Critical Neomed Inst
Publication of BR112015018317A2 publication Critical patent/BR112015018317A2/pt
Publication of BR112015018317A8 publication Critical patent/BR112015018317A8/pt
Publication of BR112015018317B1 publication Critical patent/BR112015018317B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTO DE FÓRMULA I OU UM SAL DO MESMO, COMPOSIÇÃO FARMACÊUTICA, KIT, E, USO DE UM COMPOSTO OU SAL Esta invenção refere-se geralmente aos compostos de imidazopiridina substituídos, particularmente compostos 4-(imidazo[1,2-a]piridin-2-il)benzamida substituídos e sais dos mesmos. Esta invenção refere-se também para composições farmacêuticas e kits compreendendo esse composto, usos desse composto (incluindo, por exemplo, métodos para tratar e preparações de medicamento), processos para preparar esse composto, e intermediários utilizados nesses processos.
BR112015018317-4A 2013-01-31 2014-01-31 Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica BR112015018317B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759123P 2013-01-31 2013-01-31
US61/759,123 2013-01-31
PCT/CA2014/050062 WO2014117274A1 (en) 2013-01-31 2014-01-31 Imidazopyridine compounds and uses thereof

Publications (3)

Publication Number Publication Date
BR112015018317A2 BR112015018317A2 (pt) 2017-07-18
BR112015018317A8 true BR112015018317A8 (pt) 2022-08-30
BR112015018317B1 BR112015018317B1 (pt) 2022-10-04

Family

ID=51261357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018317-4A BR112015018317B1 (pt) 2013-01-31 2014-01-31 Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica

Country Status (18)

Country Link
US (9) US9598409B2 (pt)
EP (3) EP3998267A1 (pt)
JP (1) JP6373280B2 (pt)
KR (1) KR102120513B1 (pt)
CN (2) CN105246888B (pt)
AU (1) AU2014211962B2 (pt)
BR (1) BR112015018317B1 (pt)
CA (1) CA2898665C (pt)
DK (2) DK2951177T3 (pt)
ES (2) ES2674087T3 (pt)
HK (1) HK1248138A1 (pt)
MX (1) MX2015009950A (pt)
NO (1) NO2910833T3 (pt)
PL (2) PL2951177T3 (pt)
PT (2) PT3381917T (pt)
RU (1) RU2656593C2 (pt)
TR (1) TR201807602T4 (pt)
WO (1) WO2014117274A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3998267A1 (en) 2013-01-31 2022-05-18 Bellus Health Cough Inc. Imidazopyridine compounds and uses thereof
CA2969952A1 (en) 2014-12-09 2016-06-16 Adam James Davenport 1,3-thiazol-2-yl substituted benzamides
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
EP3528813A4 (en) 2016-09-30 2020-06-03 Asana BioSciences, LLC P2X3 AND / OR P2X2 / 3 CONNECTIONS AND METHOD
EP3339307A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
ES2963702T3 (es) 2018-10-05 2024-04-01 Shionogi & Co Medicina para tratar la tos crónica
EP3863640A4 (en) * 2018-10-10 2022-07-06 Bellus Health Cough Inc. TREATMENT OF PRURITIS WITH P2X3 RECEPTOR ANTAGONISTS
US20220002292A1 (en) * 2018-11-13 2022-01-06 Bellus Health Cough Inc. Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator
WO2020135771A1 (zh) 2018-12-29 2020-07-02 武汉朗来科技发展有限公司 杂环类化合物、中间体、其制备方法及应用
AU2020228760A1 (en) * 2019-02-25 2021-09-23 Glaxosmithkline Intellectual Property (No. 3) Limited Treatment with P2X3 modulators
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
WO2021161105A1 (en) * 2020-02-14 2021-08-19 Bellus Health Cough Inc. P2x3 modulators
BR112022015818A2 (pt) * 2020-02-14 2022-10-25 Bellus Health Cough Inc Preparação de um antagonista de p2x3
CN113549068B (zh) * 2020-04-24 2022-12-02 上海拓界生物医药科技有限公司 一类新型咪唑并吡啶化合物、其制备方法及其在医药上的应用
WO2021244634A1 (zh) * 2020-06-05 2021-12-09 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
EP4169921A4 (en) * 2020-06-29 2024-06-19 Wuhan Ll Science And Tech Development Co Ltd CRYSTAL FORM OF A HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
KR20230051209A (ko) * 2020-08-13 2023-04-17 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 벤즈이미다졸 유도체, 이의 제조 방법 및 이의 의학적 용도
CN112485351A (zh) * 2020-11-18 2021-03-12 天津华津制药有限公司 一种右佐匹克隆光学异构体的检测方法
TW202227458A (zh) * 2020-12-04 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 含有稠合三環的化合物及其醫藥用途
CN114805340A (zh) * 2021-01-22 2022-07-29 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物的制备方法及其中间体
WO2022156784A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 杂环类化合物的制备方法及其中间体
WO2022258059A1 (zh) * 2021-06-10 2022-12-15 武汉朗来科技发展有限公司 一种药物组合物、制剂及其制备方法和应用
WO2022268218A1 (zh) * 2021-06-24 2022-12-29 武汉朗来科技发展有限公司 一种杂环烷基类化合物的制备方法、其中间体及其应用
CN117858870A (zh) * 2021-08-17 2024-04-09 葛兰素史密斯克莱知识产权(第3号)有限公司 P2x3拮抗剂的制备
WO2023020156A1 (zh) * 2021-08-20 2023-02-23 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US7074800B1 (en) 1999-02-10 2006-07-11 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001266232B2 (en) 2000-07-07 2005-09-15 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
SE0102808D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
KR101269869B1 (ko) 2004-09-24 2013-06-07 네오메드 인스티튜트 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도
DE102006028862A1 (de) * 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
CA2654915C (en) * 2006-06-29 2015-07-28 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
CA2755680A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
ES2442797T3 (es) 2009-11-18 2014-02-13 Neomed Institute Compuestos de benzoimidazol y sus utilizaciones
EP3998267A1 (en) 2013-01-31 2022-05-18 Bellus Health Cough Inc. Imidazopyridine compounds and uses thereof

Also Published As

Publication number Publication date
PT2951177T (pt) 2018-05-23
US9814725B2 (en) 2017-11-14
DK2951177T3 (en) 2018-06-14
DK3381917T3 (da) 2021-10-18
HK1248138A1 (zh) 2018-10-12
US20190231789A1 (en) 2019-08-01
PT3381917T (pt) 2021-10-27
ES2674087T3 (es) 2018-06-27
JP2016506935A (ja) 2016-03-07
CA2898665A1 (en) 2014-08-07
US20180015099A1 (en) 2018-01-18
BR112015018317B1 (pt) 2022-10-04
PL2951177T3 (pl) 2018-12-31
US9598409B2 (en) 2017-03-21
CN107485612A (zh) 2017-12-19
WO2014117274A1 (en) 2014-08-07
RU2656593C2 (ru) 2018-06-06
TR201807602T4 (tr) 2018-06-21
US9937185B2 (en) 2018-04-10
US20190030040A1 (en) 2019-01-31
MX2015009950A (es) 2016-02-05
US20200390779A1 (en) 2020-12-17
EP3381917A1 (en) 2018-10-03
PL3381917T3 (pl) 2021-12-27
US20150361078A1 (en) 2015-12-17
US20220062290A1 (en) 2022-03-03
EP2951177B1 (en) 2018-04-04
CA2898665C (en) 2021-02-16
EP3998267A1 (en) 2022-05-18
US20210228588A1 (en) 2021-07-29
US20200138826A1 (en) 2020-05-07
BR112015018317A2 (pt) 2017-07-18
CN105246888A (zh) 2016-01-13
AU2014211962B2 (en) 2017-11-16
ES2895225T3 (es) 2022-02-18
JP6373280B2 (ja) 2018-08-15
EP2951177A1 (en) 2015-12-09
NO2910833T3 (pt) 2018-04-07
RU2015133450A (ru) 2017-03-07
CN105246888B (zh) 2017-09-05
KR102120513B1 (ko) 2020-06-08
EP2951177A4 (en) 2016-06-01
CN107485612B (zh) 2021-03-30
AU2014211962A1 (en) 2015-08-13
EP3381917B1 (en) 2021-09-08
KR20150123812A (ko) 2015-11-04
US20170143730A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
BR112015018317A8 (pt) Composto de fórmula i ou um sal do mesmo, e, composição farmacêutica
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112018075663A2 (pt) compostos e composições para a inibição da atividade de shp2
EA201790306A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
BR112015024530A8 (pt) compostos derivados de naftiridina úteis como antagonistas de integrina alfa-v-beta-6, composição farmacêutica, e, uso de um composto
BR112012012906A2 (pt) triazolopiridinas
BR112017009601A2 (pt) derivados de aminoácidos e seus usos
BR112016029846A2 (pt) ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo?
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112013002914A2 (pt) promotores de apoptose de n-acilsulfonamida
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112015015653A8 (pt) composto, método de preparação dos compostos, composto para uso, composição farmacêutica e métodos in vitro
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BR112015017331A2 (pt) compostos químicos
BR112013002587A2 (pt) compostos químicos
AR082620A1 (es) Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: BELLUS HEALTH COUGH INC. (CA)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/01/2014, OBSERVADAS AS CONDICOES LEGAIS